
Anthem Biosciences Limited IPO
MainboardOffer Date: Jul 8, 2025 - Jul 10, 2025
₹ NaN /N/A Shares
08 Jul, 2025
Open Date10 Jul, 2025
Close Date11 Jul, 2025
Allotment Date15 Jul, 2025
Listing DateIssue Price
₹N/A per equity shareFace Value
₹2 Per Equity ShareListing at Group
BSE, NSERegistrar
Kfin Technologies LimitedMarket Lot
N/A Shares (₹N/A/-)Lead Manager
Jm Financial LimitedCitigroup Global Markets India Private Limited
J.P. Morgan India Private Limited
Nomura Financial Advisory And Securities (India) Pvt Ltd
Issue Size
OFS : Approx ₹3395 CroresRetail Portion
35%Subscription
N/A timesIPO Docs
DRHPAnthem Biosciences IPO Details
The IPO of Anthem Biosciences is priced at ₹N/A per equity share, which has a face value of ₹2 Per Equity Share each, IPO bidding starts from Jul 8, 2025 and ends on Jul 10, 2025. The allotment for Anthem Biosciences IPO will be finalized on Jul 11, 2025. Anthem Biosciences IPO will be listed on BSE, NSE, with a tentative listing date fixed as Jul 15, 2025. The company shall list its equity shares on the BSE, NSE. Kfin Technologies Limited is the registrar of the issue.
The book-running lead manager for the IPO is/are , , .
The Anthem Biosciences IPO sets its price band at N/A for each share. A single application for Anthem Biosciences Limited IPO must contain at least N/A shares.
Anthem Biosciences Valuations
EPS Pre IPO
₹/-EPS Post IPO
₹/-P/E Pre IPO
P/E Post IPO
ROE
%ROCE
%Debt/Equity
RoNW
%PAT Margin
Price to Book Value
Anthem Biosciences Company Financials All values are in ₹ Cr.
31-Mar-24 | 31-Mar-23 | 31-Mar-22 | |
---|---|---|---|
Assets | 2,398.11 | 2,014.46 | 1,618.87 |
Revenue | 1,483.07 | 1,133.99 | 1,280.24 |
Profit After Tax | 367.31 | 385.19 | 405.54 |
Net Worth | 1,924.66 | 1,740.67 | 1,355.0 |
Reserves & Surplus | 1,815.39 | 1,628.88 | 1,347.64 |
Total Borrowing | 232.53 | 125.06 | 35.49 |
About The Company
Founded in 2006, Anthem Biosciences Limited is a technology and innovation-led Contract Research, Development, and Manufacturing Organization (CRDMO) with vertically integrated operations covering drug discovery, development, and manufacturing activities.
The company caters to varied customers such as innovative, early-stage biotech companies and big pharma companies globally.The company produces niche fermentation-based APIs, such as probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.For the half-year ended September 30, 2024, the company was involved in the production of active pharmaceutical ingredients (API) and intermediates for ten commercial molecules, all of which have been funded since discovery.
The company had 196 projects as of September 30 2024: 170 discovery projects (284 synthesized molecules), 132 early phase projects, 16 late phase projects (10 late phase molecules), and 13 commercial manufacturing projects (API and intermediates for 10 commercialized molecules).
As of March 31, 2024, and September 30, 2024, the company had more than 425 and 550 customers for our CRDMO and specialty ingredients business, distributed across more than 44 countries, including Europe, Japan, and the U.S.As of March 31, 2024, the company had more than 150 customers, ranging from small biotech to big pharma.As of 30 September 2024, the company has one patent in India, seven foreign, and 24 pending foreign patent applications, including process patents for glycolipid synthesis and GLP-1 analogues.
As of 30 September 2024, the company has 600 employees, including medicinal chemists, microbiologists, molecular biologists, biochemists, specialists in different in-vivo non-clinical research and chemical engineers.
Anthem Biosciences - Promoter(s)
Pre Issue Share Holding: N/A%
Post Issue Share Holding: N/A%
- Ajay Bhardwaj
- Ganesh Sambasivam
- K Ravindra Chandrappa
- Ishaan Bhardwaj
Anthem Biosciences IPO - Issue Objectives
- The Company will not receive any proceeds from the Offer (the “Offer Proceeds”) and all the Offer Proceeds will be received by the Selling Shareholders after deduction of Offer related expenses and relevant taxes thereon, to be borne by the respective Selling Shareholders.
Other Details
Anthem Biosciences
No. 49, F1 & F2, Canara Bank Road, Bommasandra Industrial Area, Phase 1, Bommasandra, Bengaluru, Karnataka, 560099Kfin Technologies Limited
Phone: 04067162222, 04079611000
Email: anthem.ipo@kfintech.com
Anthem Biosciences IPO - FAQs
Ans. Anthem Biosciences Limited IPO is a Mainboard IPO. The issue is priced at ₹N/A per equity share. The minimum order quantity is N/A Shares. The IPO opens on Jul 8, 2025, and closes on Jul 10, 2025. Kfin Technologies Limited is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Ans. The Anthem Biosciences Limited IPO opens on Jul 8, 2025 and closes on Jul 10, 2025.
Ans. The size of Anthem Biosciences Limited IPO is OFS : Approx ₹3395 Crores.
Ans. The IPO price band is set between ₹N/A per equity share.
Ans. To apply for Anthem Biosciences Limited IPO IPO, follow the steps given below:
- - Open the IPO Ji App or Website
- - Find Anthem Biosciences Limited IPO in the List of IPOs
- - Press "Apply" Button
- - Select Your Demat Account
- - Select Your Shares Quantity and Submit
- - Track Your IPO Status
Ans. The share allotment date of Anthem Biosciences Limited IPO is Jul 11, 2025.
Ans. The Anthem Biosciences Limited IPO will be listed on Jul 15, 2025.
Ans. Follow the steps to check the allotment status for Anthem Biosciences Limited IPO here.